N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

Authors

Suresh G. Nair MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

6-2005

Published In/Presented At

D. L. Graham et al.,

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). JCO 23, 644-644(2005).

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article